Sigma Life Science launches Targeted Integration Kit
According to the company, the kit uses zinc finger nucleases (ZFNs) for heritable gene knockin at the target locus (Rosa26 or AAVS1). Sigma Life Science has also launched
Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy.